-
1Academic Journal
Συγγραφείς: A. S. Avdeeva, V. V. Rybakova, O. G. Alekseeva, E. L. Nasonov, А. С. Авдеева, В. В. Рыбакова, О. Г. Алексеева, Е. Л. Насонов
Συνεισφορές: Работа выполнена за счет средств бюджетного финансирования на выполнение государственного задания по теме AAAA-A20-120040190015-5.
Πηγή: Rheumatology Science and Practice; Vol 60, No 4 (2022); 473-480 ; Научно-практическая ревматология; Vol 60, No 4 (2022); 473-480 ; 1995-4492 ; 1995-4484
Θεματικοί όροι: биоаналог ритуксимаба, matrix metalloproteinase 3, anti-B-cell therapy, rituximab biosimilar, матриксная металлопротеиназа 3, анти-В-клеточная терапия
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/3202/2216; Насонов ЕЛ (ред.). Генно-инженерные биологические препараты в лечении ревматоидрого артрита. М.:ИМА-ПРЕСС;2013.; Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699. doi:10.1136/annrheumdis-2019-216655; Rantalaiho V, Korpela M, Laasonen L, Kautiainen H, Järvenpää S, Hannonen P, et al.; FIN-RACo Trial Group. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: The 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther. 2010;12(3):R122. doi:10.1186/ar3060; Landewé RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46(2):347-356. doi:10.1002/art.10083; Huscher D, Mittendorf T, von Hinüber U, Kötter I, Hoese G, Pfäfflin A, et al.; German Collaborative Arthritis Centres. Evolution of cost structures in rheumatoid arthritis over the past decade. Ann Rheum Dis. 2015;74(4):738-745. doi:10.1136/annrheumdis2013-204311; Насонов ЕЛ. Биоаналоги в ревматологии. Научно-практическая ревматология. 2016;54(6):628-640. [Nasonov EL. Biosimilars in rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(6):628-640 (In Russ.)]. doi:10.14412/1995-4484-2016-628-640; de Jong PH, Hazes JM, Barendregt PJ, Huisman M, van Zeben D, van der Lubbe PA, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: First results of the tREACH trial. Ann Rheum Dis. 2013;72(1):72-78. doi:10.1136/annrheumdis-2011-201162; de Jong PH, Hazes JM, Han HK, Huisman M, van Zeben D, van der Lubbe PA, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis. 2014;73(7):1331-1339. doi:10.1136/annrheumdis-2013-204788; Nam JL, Villeneuve E, Hensor EM, Wakefield RJ, Conaghan PG, Green MJ, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: The EMPIRE trial. Ann Rheum Dis. 2014;73(6):1027- 1036. doi:10.1136/annrheumdis-2013-204882; Vermeer M, Kuper HH, Hoekstra M, Haagsma CJ, Posthumus MD, Brus HL, et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: Results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum. 2011;63(10):2865-2872. doi:10.1002/art.30494; Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli G. Very early rheumatoid arthritis is the major predictor of major outcomes: Clinical ACR remission and radiographic non-progression. Ann Rheum Dis. 2011;70(7):1292-1295. doi:10.1136/ard.2010.142729; St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al.; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432-3443. doi:10.1002/art.20568; Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26-37. doi:10.1002/art.21519; Firestein G. Evolving concepts of rheumatoid arthritis. Nature. 2003;344:907-916. doi:10.1038/nature01661 15. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11:529-543. doi:10.2741/1817; Ducreux J, Durez P, Galant C, Nzeusseu Toukap A, Van den Eynde B, Houssiau FA, et al. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014;66(1):15-23. doi:10.1002/art.38202; Murphy G, Knäuper V, Atkinson S, Butler G, English W, Hutton M, et al. Matrix metalloproteinases in arthritic disease. Arthritis Res. 2002;4(Suppl 3):S39-S49. doi:10.1186/ar572; Ribbens C, Andre B, Kaye O, Kaiser MJ, Bonnet V, Jaspar JM, et al. Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not. Rheumatology (Oxford). 2000;39(12):1357-1365. doi:10.1093/rheumatology/39.12.1357; Kobayashi A, Naito S, Enomoto H, Shiomoi T, Kimura T, Obata K, et al. Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med. 2007;131(4):563-570. doi:10.5858/2007-131-563-SLOMMS; Syversen SW, Haavardsholm EA, Bøyesen P, Goll GL, Okkenhaug C, Gaarder PI, et al. Biomarkers in early rheumatoid arthritis: Longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs. Ann Rheum Dis. 2010;69(5):845-850. doi:10.1136/ard.2009.122325; Авдеева АС, Александрова ЕН, Каратеев ДЕ, Панасюк ЕЮ, Смирнов АВ, Черкасова МВ, и др. Взаимосвязь уровня матриксной металлопротеиназы-3 и деструктивных изменений суставов при раннем и развернутом ревматоидном артрите. Терапевтический архив. 2016;88(5):13-18. doi:10.17116/terarkh201688513-18; Green MJ, Gough AK, Devlin J, Smith J, Astin P, Taylor D, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford). 2003;42(1):83-88. doi:10.1093/rheumatology/keg037; Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum. 2000;43(4):852-858. doi:10.1002/1529-0131(200004)43:43.0.CO;2-7; Fujikawa K, Kawakami A, Tamai M, Uetani M, Takao S, Arima K, et al. High serum cartilage oligomeric matrix protein determines the subset of patients with early-stage rheumatoid arthritis with high serum C-reactive protein, matrix metalloproteinase-3, and MRI-proven bone erosion. J Rheumatol. 2009; 36(6):1126-1129. doi:10.3899/jrheum.080926; Авдеева АС, Александрова ЕН, Каратеев ДЕ, Лучихина ЕЛ, Черкасова МВ, Насонов ЕЛ. Роль матриксной металлопротеиназы 3 в прогнозировании эффективности терапии раннего ревматоидного артрита (исследование РЕМАРКА). Научнопрактическая ревматология. 2016;54(1):38-43. doi:10.14412/1995-4484-2016-38-43; Авдеева АС, Александрова ЕН, Новиков АА, Черкасова МВ, Панасюк ЕЮ, Насонов ЕЛ. Взаимосвязь клинической эффективности терапии тоцилизумабом с уровнем матриксной металлопротеиназы-3 в сыворотке крови у больных ревматоидным артритом. Терапевтический архив. 2013;85(5):24-29.; Tarner IH, Werner F, Schimmelpfennig C, Deten A, Oelkrug C, Müller-Ladner U, et al. SAT0039 In vivo fluorescence-imaging of matrix metalloproteinase activity and response to therapy in an animal model of rheumatoid arthritis. Ann Rheum Dis. 2012;71(Suppl 3):484.; Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH. Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression. J Rheumatol. 2000;27(12):2761-2768.; So A, Chamot AM, Péclat V, Gerster JC. Serum MMP-3 in rheumatoid arthritis: Correlation with systemic inflammation but not with erosive status. Rheumatology (Oxford). 1999;38(5):407-410. doi:10.1093/rheumatology/38.5.407; Ally MM, Hodkinson B, Meyer PW, Musenge E, Tikly M, Anderson R. Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis. Mediators Inflamm. 2013;2013:183653. doi:10.1155/2013/183653; Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 2010;62(1):33-43. doi:10.1002/art.25053; Yokoe I, Nishio S, Sato H, Kobayashi H. Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks. Mod Rheumatol. 2011;21(6):710-714. doi:10.1007/s10165-011-0474-z; Visvanathan S, Wagner C, Marini JC, Lovell DJ, Martini A, Petty R, et al.; Paediatric Rheumatology INternational Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: Analyses from a randomized, placebo-controlled trial. Pediatr Rheumatol Online J. 2010;8:24. doi:10.1186/1546-0096-8-24; Doyle MK, Rahman MU, Frederick B, Birbara CA, de Vries D, Toedter G, et al. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: Results of a phase 1, randomized, open-label trial. Rheumatology (Oxford). 2013;52(7):1214-1219. doi:10.1093/rheumatology/kes381; Urata Y, Uesato R, Tanaka D, Nakamura Y, Motomura S. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. Ann Rheum Dis. 2012;71(4):534-540. doi:10.1136/annrheumdis-2011-200108; Алексеева ОГ. Ультразвуковое исследование суставов при ревматоидном артрите: патогенетическая обоснованность, возможности использования в диагностике, оценке эффективности терапии и прогнозировании исходов. Научнопрактическая ревматология. 2018;56(1):82-92. doi:10.14412/1995-4484-2018-82-92; Осипянц РА, Каратеев ДЕ, Панасюк ЕЮ, Лукина ГВ, Смирнов АВ, Глухова СИ, и др. Оценка структурных изменений суставов кистей и темпов прогрессирования ревматоидного артрита по данным сонографии. Научно-практическая ревматология. 2013;51(2):132-137. doi:10.14412/1995-4484-2013-639; Zhou L, Wang G, Liu X, Song J, Chen L, Xu H. Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis. Arthritis Res Ther. 2017; 19(1):250. doi:10.1186/s13075-017-1449-z
-
2Academic Journal
Συγγραφείς: O. O. Portyannikova, E. N. Romanova, A. V. Govorin, S. M. Tsvinger, О. О. Портянникова, Е. Н. Романова, А. В. Говорин, С. М. Цвингер
Πηγή: The Russian Archives of Internal Medicine; Том 10, № 2 (2020); 155-160 ; Архивъ внутренней медицины; Том 10, № 2 (2020); 155-160 ; 2411-6564 ; 2226-6704 ; 10.20514/2226-6704-2020-0-2
Θεματικοί όροι: коронарный атеросклероз, matrix metalloproteinase — 3, matrix metalloproteinase — 13, osteoarthritis, coronary atherosclerosis, матриксная металлопротеиназа — 3, матриксная металлопротеиназа — 13, остеоартроз
Περιγραφή αρχείου: application/pdf
Relation: https://www.medarhive.ru/jour/article/view/1027/895; https://www.medarhive.ru/jour/article/view/1027/904; Галушко Е.А., Насонов Е.Л. Распространенность ревматических заболеваний в России. Альманах клинической медицины. 2018, 46(1): 32–39. doi:10.18786/2072-0505-201846-1-32-39; Алексенко Е.Ю., Цвингер С.М. Уровень провоспалительных цитокинов и состояние эндотелиальной функции у больных остеоартрозом в зависимости от интенсивности боли. Медицинская иммунология. 2017, 19(3): 307-312. DOI:10.15789/1563-0625-2017-3-307-312; Панина С.Б. Полиморфизмы генов как фактор риска развития остеоартроза. Медицинский вестник Юга России. 2014;(2):1320. https://doi.org/10.21886/2219-8075-2014-2-13-20; Кох Н.В., Лифшиц Г.И., Воронина Е.Н. Возможности анализа полиморфизма генов липидного обмена для выявления факторов риска развития атеросклероза. Российский кардиологический журнал 2014, 10 (114): 53–57. https://doi.org/10.15829/1560-4071-2014-10-53-057; Цвингер С.М., Говорин А.В., Портянникова О.О., Романова Е.Н. Патогенетические взаимосвязи остеоартроза и атеросклероза. ЭНИ Забайкальский медицинский вестник. 2017; (4): 164-173.; Кадурина Т.И., Горбунова В.Н. Дисплазия соединительной ткани. Руководство для врачей. Россия: ЭЛБИ — СПб. 2009; 704 с.; Тепляков А.Т., Березикова Е.Н., Шилов С.Н. и др. Оценка роли полиморфизма гена матриксной металлопротеиназы — 3 в развитии хронической сердечной недостаточности. Тер. Архив. 2015. 87(4): 8-12. doi:10.17116/terarkh20158748-12.; Mittаl B., Mishrа А., Srivаstаvа А., Kumаr S., Gаrg N. Mаtriх mеtаllоprоtеinаsеs in cоrоnаry аrtеry disеаsе. Аdv Clin Chеm 2014; 64: 1—72; Arden N., Blanco F.J., Bruyere O. et al. Atlas of osteoarthritis. Second edition. European Society for clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). ISBN 978-1-910315-68-2 (Print), 2018; 19-21.; Джазаева М.Б., Гладких Н.Н., Решетников В.А., Ягода А.В. Матриксные металлопротеиназы: значение в ремоделировании сердца у пациентов с дисплазией соединительной ткани. Медицинский вестник Северного Кавказа. 2018; 13(4): 576-580. https://doi.org/10.14300/mnnc.2018.13108.; https://www.medarhive.ru/jour/article/view/1027
-
3Academic Journal
Συγγραφείς: A. S. Avdeeva, E. N. Aleksandrova, D. E. Karateev, E. L. Luchikhina, M. V. Cherkasova, E. L. Nasonov, А. С. Авдеева, Е. Н. Александрова, Д. Е. Каратеев, Е. Л. Лучихина, М. В. Черкасова, Е. Л. Насонов
Πηγή: Rheumatology Science and Practice; Vol 54, No 1 (2016); 38-43 ; Научно-практическая ревматология; Vol 54, No 1 (2016); 38-43 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20161
Θεματικοί όροι: генно-инженерные биологические препараты, matrix metalloproteinase 3, methotrexate, biological agents, матриксная металлопротеиназа 3, метотрексат
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/2167/1389; Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология: Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290-331 [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In.: Nasonov EL, Nasonova VA, editors. Revmatologiya: Natsional'noe rukovodstvo [Rheumatology: National guidelines]. Moscow: GEOTAR-Media; 2008. P. 290-331].; Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010 [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical Recommendations]. Moscow: GEOTAR-Media; 2010].; Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-75. doi:10.1136/ard.2009.126532; Rantalaiho V, Korpela M, Laasonen L, et al; FIN-RACo Trial Group. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther. 2010;12:R122. doi:10.1186/ar3060; Landewe RB, Boers M, Verhoeven AC, et al.COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis pheum. 2002;46:347-56. doi:10.1002/art.10083; De Jong PH, Hazes JM, Barenndregt PJ, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis. 2013;72:72-8. doi:10.1136/annrheumdis-2011-201162; De Jong PHPD, Hazes JM, Luime JJ, et al. Randomized comparison of triple DMARD therapy with methotrexate mono-therapy. Ann Rheum Dis. 2013;72(Suppl 3):113. doi:10.1136/annrheumdis-2013-eular.382; Villeneuve E, Nam JL, Hensor E, et al. Preliminary results of a multicenter randomosed controlled trial of etanercept and methotrexate to induce remission in patients with newly diagnosed inflammatory arthritis. Arthritis Rheum. 2011;63:S96-S961.; Vermeer M, Kuper HH, Hoekstra M, et al. Implementation of a Threat-to-Target Strategy in very Early Rheumatoid Arthritis. Results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort Study. Arthritis Rheum. 2011;63:2865-72. doi:10.1002/art.30494; Bosello S, Fedele AL, Peluso G, et al. Very early rheumatoid arthritis is the major predictor of major outcome: clinical ACR remission and radiographic non-progression. Ann Rheum Dis. 2011;70:1292-5. doi:10.1136/ard.2010.142729; St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432-43. doi:10.1002/art.20568; Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study – a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37. doi:10.1002/art.21519; Van Nies JA, Gaujoux-Viala C, Tsonaka R, et al. When does the therapeutic window of opportunity in rheumatoid arthritis close? A study in two early RA cohorts. Ann Rheum Dis. 2014;73(Suppl 2):73. doi:10.1136/annrheumdis-2014-eular.5266; Burrage P, Mix K, Brinckerhoff C. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11:529-43. doi:10.2741/1817; Murphy G, Knauper V, Atkinson S, et al. Matrix metalloproteinases in arthritic disease. Arthritis Res. 2002;4(Suppl 3):39-49. doi:10.1186/ar572; Flannery C. MMPs and ADAMTSs: functional studies. Front Biosci. 2006;11:544-69. doi:10.2741/1818; Ribbens C, Andre B, Kaye O, et al. Synovial fluid matrix metalloproteinase 3 levels are increased in inflammatory arthritis whether erosive or not. Rheumatology. 2000;39:1357-65. doi:10.1093/rheumatology/39.12.1357; Posthumus MD, Limburg PC, Westra J, et al. Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression. J Rheumatol. 2000;12(27):2761-8.; Green M, Gough A, Devlin J, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology. 2003;42:83-8. doi:10.1093/rheumatology/keg037; So A, Chamot AM, Peclat V, Gerster JC. Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status. Rheumatology. 1999;38:407-10. doi:10.1093/rheumatology/38.5.407; Ally M, Hodkinson B, Meyer P, et al. Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis. Mediators Inflamm. 2013; pub online 2013 April 7. doi:10.1155/2013/183653; Kobayashi A, Naito S, Enomoto H, et al. Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med. 2007;131:563-70.; Syversen S, Haavardsholm E, Boyesen P, et al. Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs. Ann Rheum Dis. 2010;69:845-50. doi:10.1136/ard.2009.122325; Posthumus M, Limburg P, Westra J, et al. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. J Rheumatol. 2002;29:883-89.; Garnero P, Thompson E, Woodworth T, Smolen J. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate. Arthritis Rheum. 2010;62:33-43. doi:10.1002/art.25053; Yokoe I, Nishio S, Sato H, Kobayashi H. Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks. Mod Rheumatol. 2011;21:710-4. doi:10.3109/s10165-011-0474-z; Visvanathan S, Wagner C, Marini J, et al. The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. Ped Rheumatol. 2010;8:24.; Doyle M, Rahman M, Frederick B, et al. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. Rheumatology. 2013;52:1214-9. doi:10.1093/rheumatology/kes381; Каратеев ДЕ, Лучихина ЕЛ, Муравьев ЮВ и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Научно-практическая ревматология. 2013;51(2):117-25 [Karateev DE, Luchikhina EL, Muravyev YV, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(2):117-25. (In Russ.)]. doi:10.14412/1995-4484-2013-637; Fransen J, Stucki G, van Reil PLCM. Rheumatoid arthritis measures. Arthritis Rheum. 2003;49:214-24. doi:10.1002/art.11407; Aletaha D, Nell V, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7:R796-806.; Tarner IH, Werner F, Schimmelpfennig C, et al. In vivo fluorescence-imaging of matrix metalloproteinase activity and response to therapy in an animal model of rheumatoid arthritis. Ann Rheum Dis. 2012;71(Suppl 3):484. doi:10.1136/annrheumdis-2012-eular.2987; Urata Y, Uesato R, Tanaka D, et al. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. Ann Rheum Dis. 2012;71:534-40. doi:10.1136/annrheumdis-2011-200108; Visvanathan S, Marini J, Smolen J, et al. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. J Rheumatol. 2007;34:1465-74.; Kaneko A, Kida D, Saito K, et al. Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI. Rheumatol Int. 2012;32(11):3631-7. doi:10.1007/s00296-011-2256-5